Nuvectis Pharma(NVCT) - 2025 Q2 - Quarterly Results

The increase in net loss in the second quarter of 2025 was primarily due to the NXP900 DDI study, which has been completed. The three months ended June 30, 2025, also includes $1.8 million of non-cash stock-based compensation. Exhibit 99.1 Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights August 5, 2025, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati ...